Russian Direct Investment Fund on Friday said a preliminary laboratory study conducted by the Gamaleya Center has demonstrated that the Sputnik V vaccine and the one-shot Sputnik Light booster were effective against the Omicron variant of Covid-19. Heterologous boosting with Sputnik Light is the solution to increase other vaccines' efficacy, including against Omicron, and extend the booster protection period, RDIF …
In a clinical trial conducted in Azerbaijan, a combination of the AstraZeneca vaccine and the first component of the Sputnik V vaccine showed a high immunogenicity profile. According to the Russian Direct Investment Fund, Russia’s sovereign wealth fund, along with AstraZeneca and R-Pharm, the two vaccines combined have shown promising immunogenicity results. As a result of this approach’s success in …
A combination of the AstraZeneca vaccine and the first component of the Sputnik V vaccine has shown high immunogenicity profile in a clinical study conducted in Azerbaijan. The Russian Direct Investment Fund, Russia’s sovereign wealth fund, AstraZeneca and R-Pharm have announced the preliminary results of immunogenicity of the combined use of the two vaccines. The heterogeneous boosting approach or ‘vaccine …
Moscow: Announcing the initial safety results of the world's first study of a combination of the AstraZeneca and Sputnik V COVID-19 vaccines, the Russian Direct Investment Fund, on Friday said that interim analysis of the data demonstrates a high safety profile for the combined use of the vaccines with no serious adverse events or cases of coronavirus after vaccination. "The …
